Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.
Follow-Up Questions
¿Quién es el CEO de Impact Biomedical Inc?
Mr. Frank Heuszel es el Chairman of the Board de Impact Biomedical Inc, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción IBO?
El precio actual de IBO es de $0.6594, ha increased un 0.16% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Impact Biomedical Inc?
Impact Biomedical Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Impact Biomedical Inc?
La capitalización bursátil actual de Impact Biomedical Inc es $8.0M
